Celltrion Holdings to cease selling shares internationallyCelltrion, a Korean biopharmaceutical company listed on the Kosdaq market, yesterday announced that its largest shareholder Celltrion Holdings will stop selling its shares to transnational pharmaceutical companies.
The company pushed for an M&A in an effort to boost competitiveness in the global market, but the decision will become a shift in its marketing strategy, choosing to strengthen its sales network overseas.
The company’s foreign investors made the decision because they concluded that the M&A may raise financial uncertainties at a time when its stronghold biosimilar product Remsima is selling well in Europe.
More in Industry
Soaring iron ore prices batter Korea's steelmakers
BTS among performers at Lotte Duty Free 40th anniversary concert
[TEST DRIVE] New Chevrolet Colorado can handle anything Korea throws at it
Tada tries again with new taxi ride-hailing service
Kia plant hit with infections for second time this month